Transaction in Own Shares

Summary by AI BETAClose X

Craneware plc has completed its share buyback programme, purchasing 43,134 ordinary shares on May 12, 2026, at a volume-weighted average price of 1,501.21 GBp per share, with the lowest price paid being 1,486.00 GBp and the highest 1,502.46 GBp. This transaction utilized the remaining $25 million allocated for the programme, which commenced on March 16, 2026. In total, 1,276,957 ordinary shares have been repurchased and will be held in treasury. Following these purchases, the company has 34,237,148 ordinary shares in issue, excluding treasury shares.

Disclaimer*

Craneware plc
13 May 2026
 

13 May 2026

 

Craneware plc

 ("Craneware", or the "Company")

 Transaction in Own Shares and Completion of Share Buyback Programme

 

Craneware (AIM: CRW.L), a leader in healthcare financial performance solutions, announces it has purchased the following number of its Ordinary Shares of 1p each through Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg") on the London Stock Exchange.

 

Date of purchases:

12 May 2026

Aggregate number of Ordinary Shares purchased:

                 43,134

Lowest price paid per share (GBp):

                1,486.00

Highest price paid per share (GBp):

                1,502.46

Volume weighted average price paid per share (GBp):

                1,501.21


The Company will hold the purchased shares in Treasury. Following the purchase of these shares, the Company will have 34,237,148 Ordinary Shares in issue (excluding Treasury shares), and the Company will hold 1,305,021 Ordinary Shares in Treasury.

 

The figure of 34,237,148 represents the total voting rights in the Company and may be used by shareholders as the denominator for calculating whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The table below contains detailed information about the purchases made as part of the buyback programme which was announced by the Company on 16 March 2026 (the "Programme").

 

Schedule of Purchases - Individual Transactions

 

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 as it forms part of UK law, a full breakdown of the individual trades made by Berenberg on behalf of the Company as part of the Programme is detailed below:

 

Number of ordinary shares purchased

Transaction price (GBp share)

Time of transaction (UK Time)

Transaction

reference number

Trading Venue

 


39,778

1502.46

12.05.2026 11:02:10

00067387093TRLO1

LSE


3,085

1486.00

12.05.2026 11:27:24

00067387883TRLO1

LSE


271

1491.00

12.05.2026 11:38:22

00067388140TRLO1

LSE


 

 

Completion of the Share Buyback Programme

 

Following the above transaction, the Company has now utilised the $25m which was announced as part of the FY26 Interim Results and later commenced on 16 March 2026 for the current Share Buyback Programme. In total, the Company has repurchased 1,276,957 Ordinary Shares of 1p each, all of which will be held in Treasury (to cover existing share options and long-term incentive plan awards which have been granted by the Company to employees).

 

 

For further information please contact:

 

Craneware plc                                                                                                                                                +44 (0)131 550 3100

Keith Neilson, CEO

Craig Preston, CFO

 

Alma Strategic Communications                                                                                                               +44 (0)20 3405 0205

Caroline Forde, Kinvara Verdon, Louisa El-Ahwal                                                                     craneware@almastrategic.com

 

About Craneware

 

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster - that simplify the complexities of healthcare finance and operations. What sets us apart is our unique combination of deep healthcare expertise and engineering excellence, positioning us as a strategic partner rather than just a technology provider. The Craneware Group empowers healthcare organizations to achieve sustainable financial success while delivering better outcomes for the communities they serve - today and in the future. Together, we are transforming the business of healthcare.

 

Learn more at www.thecranewaregroup.com

 

 

 

 

 

 

                                                                                                                       

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Craneware (CRW)
UK 100

Latest directors dealings